ASRT Stock Recent News
ASRT LATEST HEADLINES
Assertio (ASRT) appoints Heather Mason as its interim CEO as its current CEO, Dan Peisert, steps down from his role. Shares of the company fall on the same.
Today's backdrop of a predicted fall in interest rates, as well as the expectation that indices like the S&P 500 will surge higher, has some important considerations for penny stocks. Penny stocks tend to do better when the downward pressures on their valuations subside.
Assertio Holdings Inc. (NASDAQ:ASRT ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Matt Kreps - Darrow Associates, IR Dan Peisert - President and CEO Ajay Patel - SVP & Chief Accounting Officer Paul Schwichtenberg - SVP & CFO Conference Call Participants Thomas Flaten - Lake Street Capital Markets Jim Sidoti - Sidoti Scott Henry - ROTH MKM Partners Operator Good morning and welcome to the Assertio Holdings Inc. Third Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode.
LAKE FOREST, Ill., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it will release third quarter 2023 financial results on Wednesday, November 8, 2023, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.
Assertio Holdings has undergone a significant transformation in its business model, reducing debt and exiting the opioid business. The company's recent performance has shown strong growth, with increased net product sales and improved gross margin. Assertio's stock is currently undervalued, trading at a significant discount, and has the potential for future growth and a turnaround.
Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.
Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.
Assertio (NASDAQ: ASRT ) stock is falling hard on Friday after the pharmaceutical company released its Q2 earnings report. Assertio disappointed investors with its adjusted earnings per share of 19 cents.
The stock is down 33% from its 52-week high. Q2 revenue estimates are low. Lead product's use may be expanding.
Spectrum stockholders will receive contingent value rights, too, along with Assertio shares. The rewards are payable on achievement of 2024 and 2025 sales levels from Spectrum's lead drug. Rolvedon has already reached the first (hardest) target in Q1 without the help of a J-Code that took effect at the beginning of Q2.